Metagenomi Therapeutics (MGX) executive compensation, 2026 proxy

Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer, was paid $1.7M in 2025, down 56% from $3.8M the year before.

Filed
April 27, 2026
Annual meeting
June 9, 2026
Pay year
2025
Named executives
4
CEO total pay
$1.7M-56% vs prior year
CEO pay in equity
50%$830,742 in awards
Bonus Payout Percentage
85%Of target for eligible NEOs

How M.B.A. was paid

$1.7M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary34%Stock awards26%Option awards24%Non-equity incentive15%All other compensation1%

Named executive officers

ExecutiveTotal
Brian C. Thomas, Ph.D.Former Chief Executive Officer$1,396,061
Jian Irish, Ph.D., M.B.A.President and Chief Executive Officer$1,667,920
Pamela Wapnick, M.B.A.Chief Financial Officer$934,964
Matthew L. Wein, J.D.General Counsel, Compliance Officer, Head of BD&L and Corporate Secretary$756,384

What changed and why

  • $1.7MJian Irish served as President and Chief Executive Officer at fiscal year end with a total compensation of $1,667,920.
  • $1.4MBrian C. Thomas served as former Chief Executive Officer and received total compensation of $1,396,061.
  • 85%Annual cash bonuses were paid at 85% of target for eligible named executive officers based on performance goals.
  • 100%Employer matching contributions of 100% were provided on the first 5% of participant compensation contributed to the 401(k) plan.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.